22 Sep, 2023 Diagnosed prevalent cases of heart failure in 7MM to surpass 16 million in 2032, forecasts GlobalDataPosted in Pharma
The diagnosed prevalent cases of heart failure (HF) in the seven major markets (7MM*) are set to register an annual growth rate (AGR) of 1.68% from 13.76 million in 2022 to 16.07 million in 2032, forecasts GlobalData, a leading data and analytics company.
GlobalData’s latest report, “Heart Failure – Epidemiology Forecast to 2032,” reveals that in 2032, the US will have the highest number of diagnosed prevalent cases of HF among the 7MM at 7.35 million cases, whereas Spain, with nearly 0.77 million cases, will have the lowest number.
Antara Bhattacharya, Associate Project Manager from Pharma – Epidemiology team at GlobalData, comments: “Both men and women can be affected, however HF is more prevalent among men and in the elderly population.”
Adults ages 60 years and above accounted for almost 85% of the diagnosed prevalent cases of HF in the 7MM while those in younger adults ages 19–59 years accounted for almost 14% of the cases. Children ages 18 years and younger accounted for 0.37% of the cases. This is apparent from GlobalData estimates for age-specific diagnosed prevalent cases. HF-REF (LVEF<40%) accounted for approximately 47% of the diagnosed prevalent cases of HF in the 7MM in 2022.
Bhattacharya concludes: “There is an increased need for individualization of in-hospital management, including treatments targeting the causative factors, and continuation of treatment after hospital discharge to improve long-term outcomes especially for acute HF.
“The case mix of HF is evolving, more epidemiological data on acute HF can improve the treatment outcomes. With early diagnosis and lifestyle modifications, more people with HF can perform well. With respect to HF treatment, awareness among physicians, and obtaining the optimal management of HF patients while preventing underutilization, or suboptimal dosing of guideline-directed medical therapy is necessary for improving functional status, quality of life, and survival in patients with HF.”
*7MM: The US, 5EU (France, Germany, Italy, Spain, the UK), and Japan.